Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102 Blog Post

Minoryx Therapeutics, a drug development company specialized in the discovery and development of new drugs for orphan diseases, today announces the initiation of its first-in-man Phase 1clinical trial for its lead compound MIN-102. The company –located at TecnoCampus Mataró-Maresme, with laboratories at Barcelona Science Park (PCB)– will harness its unique mechanism of action for potential use in X-linked Adrenoleukodystrophy (X-ALD), a genetic disease characterized by progressive neurologic deterioration with no available pharmacological treatment. 

 

Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome Blog Post

Avizorex Pharma –an ophthalmology biotech company with offices at Barcelona Science Park (PCB)– announces the submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority, requesting clearance to initiate a Phase I/II clinical trial investigating the use of AVX-012 Ophthalmic Solution, a small molecule with a novel mechanism of action to treat patients suffering from mild to moderate Dry Eye Syndrome (DES). 

 

Using 3D printing to produce crucial biomedical research tools Blog Post

IBEC Director Josep Samitier and the Technology Transfer unit introduced IBEC’s 3D bioprinting capabilities at the first IN(3D)USTRY: From Needs to Solutions event, which was held at Fira Barcelona last week. IBEC’s 3D bioprinter is the only one offering the level of precision and characteristics requred for regenerative medicine purposes in southern Europe, and one of very few on the continent. It promises to put IBEC –based at Barcelona Science Park (PCB)– at the forefront of a new revolution in regenerative medicine by allowing researchers to add biological properties to implanted tissues such as bone, and may eventually be able to manufacture entire organs for transplantation.

 

Biocat and Leitat will coordinate two of the five RIS3CAT Communities Blog Post

The RIS3CAT Community for Digital applications in biotechnology and health therapies –coordinated by Biocat from its headquarters at the Barcelona Science Park (PCB)– is one of the first RIS3CAT Communities to which Government of Catalonia, through ACCIÓ, has allocated 19.1 million Euros from the ERDF fund (European Regional Development Fund). Leitat –whose BioMed Division is based at PCB– will also coordinate a further RIS3CAT Community for New diagnostic devices and big data applied to health, in which Intelligent Pharma, located at PCB, leads one of the four projects: ‘Diabetes as an accelerator of cognitive derioration in Alzheimer´s disease: Integral approach and treatment adherence’.

 

EIT Health launches two funding calls for innovative health projects Blog Post

EIT Health has lunched two funding initiatives: the grants Headstart and Proof of Concept and the Business Plan Aggregator program. As part of the EIT Health accelerator, both ideas are geared to innovative business ideas, SMEs, spin-offs and start-up committed to the social challenges defined by EIT´s principles: promoting a healthy lifestyle, supporting active ageing and improving quality of life through better healthcare. EIT Health Spain is based at the Barcelona Science Park (PCB) and at presently brings together 18 leading public and private organizations in the three areas of the innovation triangle: research, education and business creation.

 

The turnonver of the 734 companies of the BioRegion amounts to 7% of Catalonia´s GDP Blog Post

The life sciences and healthcare sector of Catalonia gathers 734 companies with a turnover of 14.360 million euros, 7% of Catalonia’s GDP and employs 42,133 workers. These are some of the data yielded by the 2015 Biocat Report, presented last Thursday at the Palau de la Generalitat, which brought more than 200 politicians, business people and figures from academia and science. The event was presided over by the President of the Government of Catalonia, Carles Puigdemont, with the participation of Albert Barberà, CEO at Biocat, the organization that coordinates and promotes the health and life sciences sector in Catalonia, and Ella Korets-Smith, executive director of TO Health!, the Toronto´s life science cluster. 

 

IDP Pharma closes a funding round for 2 million euros Blog Post

IDP Pharma, founded in 2015 and with headquarters at the Barcelona Science Park (PCB) has raised, during its first operative year, over 2 million euros from public and private capital. The biopharmaceutical company –specializes in the development of drugs for cancer treatment directed to a new class of therapeutic targets: IDPs– will appoint this capital to continue the preclinical development of their most advanced products: two first-in-class molecules with antitumor activity for Multiple Myeloma, the second most common blood cancer

 

Mind the Byte launches six new software to accelerate drug discovery Blog Post

In line with the ground-breaking pay-per-use philosophy, Mind the Byte has launched six new programs for computational drug design on their SaaS platform (Software as a Service), which the company has been marketing since 2011. The new software expands the services currently on offer and helps cut drug-development time and costs up to 30% for companies and researchers. The products were launched at prices that adapt to the needs of each user.